Medical Claims - Betty Nguyen Davis

Medical Malpractice

Betty Nguyen Davis Team — Sun, 30 Jan 2022 00:00:00 GMT

Georgia victims of medical malpractice often find themselves burdened with medical bills, the need for extended professional care, and the inability to earn a living because of debilitating injuries. Under the worst circumstances, family members are left to grieve for the wrongful death of a loved one due to the carelessness of a medical provider. When medical professionals make mistakes, Georgia law allows patients who have suffered from the consequences of substandard treatment and their families to recover monetary damages for medical bills and for pain and suffering. If you or a family member has been a victim of medical malpractice in Georgia, please contact The Davis Injury Firm LLC for a consultation.

Georgia C.R. Bard Davol Surgical Mesh

Betty Nguyen Davis Team — Sat, 17 Jul 2021 00:00:00 GMT

The U.S. Food and Drug Administration issued a recall on Bard Davol surgical meshes that were distributed under the C.R. Bard Davol brand name but later discovered to be counterfeit mesh. The Bard/Davol mesh is typically used for hernia surgery repair by covering the weakened or torn tissue in the body and closed into the body; thus, the use of a counterfeit mesh could cause serious post-operative damage to patients. The counterfeit hernia mesh was distributed by RAM Medical Inc. and then redistributed to hospitals and other medical providers through Medline Industries, Amerimed Corporation, Henry Schein Inc., Marathon Medical Corporation, MMS-A Medical Supply Company, and Q-Med Corporation. According to the FDA, the counterfeit product was distributed between October 2008 and October 2009. If you had surgery that involved the use of the counterfeit Bard Davol mesh, you could have a claim for personal injury, as the mesh was not sterile and could lead to infection and may have an increased likelihood of unraveling in the body. Please call The Davis Injury Firm at (404) 593-2620 for more information on the counterfeit Bard Davol mesh product.

Georgia DePuy Hip Implant Recall

Betty Nguyen Davis Team — Wed, 14 Jul 2021 00:00:00 GMT

Patients in Georgia who have received DePuy ASR hip implants may have claims for defective product liability if their implants failed. In 2010, after years of receiving complaints from patients and doctors that their hip implants were causing complications, DePuy Orthopedics Inc. recalled two of its DePuy ASR (Articular Surface Replacement) Hip Implants. Studies showed that patients who received the ASR hip implants experienced pain that required second hip replacement surgeries. The DePuy implants have caused patients to experience hip failures, metallosis, and cobaltism (a blood disorder that causes serious injuries, cancer, or even death if untreated) because it exposes patients’ bloodstreams to toxic levels of cobalt and chromium. Patients who have experienced hip pain, metallosis, cobaltism, or a failed hip replacement device from DePuy must have the ASR hip replaced.

Defective Transvaginal Surgical Mesh Patch FDA Alert

Betty Nguyen Davis Team — Fri, 09 Jul 2021 00:00:00 GMT

Many women in Atlanta, Georgia, and all around the country have experienced complications from transvaginal mesh patches that have been used to treat pelvic organ prolapse (POP) or stress urinary incontinence (SUI) and have initiated the help of Georgia lawyers to recover compensation for medical bills and pain and suffering associated with their problems.

In July 2011, the FDA issued a warning about several surgical mesh slings that have been implanted in women, stating that those products have caused further complications such as vaginal infections, chronic vaginal drainage, bleeding, pain during intercourse, urinary leakage and incontinence, organ perforation, recurrence of the prolapsed organs, erosion of vaginal tissue, and backaches. Unfortunately, many women have continued to suffer after their initial POP or SUI surgeries and have been required to follow up surgeries to remove the mesh and correct these problems. According to the FDA, there were 2,874 reports of complications related to transvaginal mesh devices between 2008 and 2010. In addition, the FDA stated that there is no evidence that the use of transvaginal mesh for POP repair provides better results than non-mesh repair methods and could expose patients to higher risks.

If you are experiencing complications such as pain, bleeding, and infections from a POP or SUI repair surgery in Georgia, you may be entitled to compensation by holding the manufacturers of these defective products liable for placing such unsafe products on the market. Some of the dangerous products used include Bard Avaulta Solo, Avaulta Plus, and Avaulta Biosynthetic systems. The manufacturers of these products include C.R. Bard, Johnson & Johnson Ethicon, American Medical Systems, Boston Scientific Scimmed, Sofradim, Caldera, and Mentor Corporation. If you or a loved one has experienced pain after surgery using a transvaginal mesh product and need the guidance and support of a defective medical products attorney in Georgia, please call The Davis Injury Firm at (404) 593-2620 for a confidential consultation with a female lawyer.

Xarelto Trials Decided in Favor of Bayer Ag, Janssen Pharmaceuticals, and Johnson & Johnson

Betty Nguyen Davis Team — Sun, 27 Jun 2021 00:00:00 GMT

On May 3, 2017, a jury in New Orleans found in favor of the manufacturers of the blood thinner Xarelto in a lawsuit that Joseph Boudreaux filed against Bayer AG, Janssen Pharmaceuticals, and Johnson & Johnson after Mr. Boudreaux’s was hospitalized for gastrointestinal bleeding that required multiple blood transfusions. The Boudreaux case was based on a failure to warn theory, where the plaintiff alleged that the manufacturers of the drug did not adequately warn him about the dangers and risks of Xarelto. The defense of the case was based on the learned intermediary doctrine, which allows a drug manufacturer to warn a medical professional about the dangers of a drug rather than to the patient directly.

On June 12, 2017, the drug manufacturers won a second bellwether case based on the death of Sharyn Orr, who died after suffering from hemorrhaging in her brain after taking Xarelto. Ms. Orr required surgery, but her doctor did not operate because Xarelto was still in her system; by the time she could have the surgery, it was too late, and Ms. Orr passed away. The plaintiff’s lawyers alleged that the drug manufacturers not only failed to adequately warn Ms. Orr and her doctors, they also failed to create a monitoring plan and properly instruct doctors to conduct a blood test that would allow them to predict which patients are most susceptible to internal bleeding from taking Xarelto.

The Boudreaux and Orr cases are just two out of 40 or so “bellwether” trials (test trials that are conducted to help determine value where there are a heavy volume of similarly based cases, typically in multidistrict litigation that is scheduled in the Xarelto multidistrict litigation. Thus, there is still hope that plaintiffs will win some of the future Xarelto cases. There are currently 18,000 or so Xarelto claims pending, and the results of the bellwether trials will help shape the future of the claims process.

Xarelto is an anticoagulant drug that is often prescribed to prevent pulmonary embolism, deep vein thrombosis, and other serious conditions. Patients who have taken Xarelto have experienced internal hemorrhaging leading to serious injuries or even death. Unlike other anticoagulant medications (for example, vitamin K may be used to stop bleeding where the patient is taking Coumadin), there is no way to stop internal bleeding, so a patient who is taking Xarelto and experiencing internal bleeding has to wait until the body stops bleeding on its own.

The sale of Xarelto has generated billions of dollars for drug companies. In the first quarter of 2017, increased sales of Xarelto in Europe and Japan helped Bayer post a 9.6% rise in revenue. Interestingly, Johnson & Johnson announced sales of Xarelto in the U.S. decreased by 9.5% in the first quarter of 2017 (it was still $513 million) and was due to discounting. It does not look like Xarelto is going to be taken off of the market, despite its dangers!

The attorneys at Betty Davis Law are still evaluating, investigating, and accepting Xarelto cases where patients have experienced severe internal bleeding (gastrointestinal, rectal, and brain bleed) or even death. Our firm has filed multiple lawsuits against Bayer AG, Janssen, and Johnson & Johnson on behalf of patients who took Xarelto. If you or a loved one has been hospitalized from the deadly side effects of Xarelto, please call (404) 593-2620.